Core Viewpoint - Nexalin Technology, Inc. has appointed Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs, bringing over 30 years of experience in the medical device industry to the company [1][3] Company Overview - Nexalin Technology designs and develops innovative neurostimulation products aimed at addressing the global mental health epidemic, utilizing bioelectronic medical technology to treat mental health issues [4] Leadership Appointment - Carolyn Shelton's extensive background includes leadership roles at Openwater Health, Advanced Sterilization Products, and Medtronic, where she successfully navigated complex regulatory landscapes and led clinical trials [2][3] - Shelton's experience includes filing for FDA Breakthrough designation and achieving compliance with the EU MDR, which will be crucial for Nexalin's future regulatory submissions [2][3] Strategic Importance - The appointment of Shelton is seen as a strategic addition to Nexalin's executive team, particularly as the company prepares for international rollout of its Deep Intracranial Frequency Stimulation (DIFS) technology and seeks future FDA Breakthrough Device designations [3] - Shelton expressed enthusiasm about joining Nexalin, highlighting the unmet need for effective, drug-free alternatives for treating mental health conditions [3]

Core Insights - Nexalin Technology, Inc. participated in a Congressional roundtable in North Carolina focused on virtual therapeutic options for opioid treatment, highlighting its commitment to addressing the opioid crisis [1][2][3] Group 1: Congressional Roundtable - The roundtable was hosted by the Breaking Barriers for Substance Use Recovery initiative and included key stakeholders from healthcare and policy sectors [1] - U.S. Congressman Dr. Greg Murphy, an advocate for innovative healthcare solutions, led discussions on deploying virtual-based opioid therapy models nationwide [2] - The event aimed to address the stigma and geographic barriers associated with traditional in-clinic treatment options [3] Group 2: Nexalin's Role and Technology - Nexalin's virtual therapeutic solutions were emphasized as promising tools in combating opioid addiction, pending FDA clearance [3] - The company aims to provide effective and accessible treatment options, particularly for veterans in rural communities [4] - Nexalin's neurostimulation technology is designed to penetrate deep brain structures associated with mental health disorders, potentially enhancing patient response without adverse side effects [5] Group 3: Industry Implications - Discussions at the roundtable focused on improving practices within the Department of Veterans Affairs (VA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) to promote virtual therapies [4] - The meeting aligns with Nexalin's efforts to expand its influence within U.S. Government areas of interest, particularly in mental health care [4]

Established as a tax-exempt organization, Breaking Barriers to Substance Use Recovery is focused on identifying and dismantling the obstacles to effective treatment for opioid use disorder. Breaking Barriers to Substance Use Recovery brings together bringing together a broad cross section of leaders in the medical and science and technology industries to develop and formulate pioneering and innovative solutions to combat the opioid crisis. The organization also advocates for the adoption of comprehensive po ...

Nexalin CEO Mark White Participates in Inaugural Meeting Established as a tax-exempt organization, Breaking Barriers to Substance Use Recovery is focused on identifying and dismantling the obstacles to effective treatment for opioid use disorder. Breaking Barriers to Substance Use Recovery brings together bringing together a broad cross section of leaders in the medical and science and technology industries to develop and formulate pioneering and innovative solutions to combat the opioid crisis. The organiz ...

HOUSTON, TX, July 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the "Company" or "Nexalin") today announced the closing of its previously announced public offering of 3,000,000 shares of common stock at public offering price of $1.75. Gross proceeds, before deducting placement agent fees and other offering expenses were approximately $5,250,000. The securities described above were offered pursuant to a registration statement on Form S-1, as amended (File No. 333-279684) (the "R ...

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with ...

Nexalin Technology (NASDAQ:NXL) stock is down on Friday after the medical device company priced a public offering of its shares. Nexalin Technology is selling 3 million shares of NXL stock for $1.75 each in this public offering. This has the company expecting gross proceeds from the offering to come in at $5.25 million. Nexalin Technology notes that Maxim Group LLC is acting as the sole placement agent for the offering. The company is also expecting this offering to close on Monday. What This Means for NXL ...

The securities described above were offered pursuant to a registration statement on Form S-1, as amended (File No. 333-279684) (the "Registration Statement"), which was declared effective by the Securities and Exchange Commission (the "SEC") on June 27, 2024. The offering was made only by means of a prospectus which is a part of the Registration Statement. A final prospectus relating to the offering will be filed with the SEC. Copies of the final prospectus relating to this offering may be obtained from Max ...

Company Overview - Nexalin Technology, Inc. designs and develops innovative neurostimulation products aimed at addressing the global mental health epidemic, utilizing bioelectronic medical technology to treat mental health issues [4]. Public Offering Details - The company announced a public offering of 3,000,000 shares of common stock at a public offering price of $1.75, expecting gross proceeds of approximately $5,250,000 before deducting fees and expenses [3][6]. Product Information - Nexalin's neurostimulation devices are designed to be non-invasive and undetectable, targeting deep structures in the mid-brain associated with mental health disorders. The next-generation devices are believed to enhance patient response without adverse side effects [4]. Regulatory and Compliance - The offering is conducted under a registration statement on Form S-1, which was declared effective by the SEC on June 27, 2024, and the final prospectus will be filed with the SEC [8].

HOUSTON, June 26, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW))) (the "Company" or "Nexalin") today announced positive results of a clinical study designed to evaluate the feasibility, safety, and efficacy of transcranial alternating current dynamic frequency stimulation (tACS) as an add-on treatment for the symptoms of major depressive disorder (MDD), also known as clinical depression, a mental health condition that affects mood, behavior, appetite, and sleep. The results of the st ...